Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1989 Feb;66(2):264–269.

Inhibition of immune haemolysis by a serum factor found in C3-deficient subjects.

H Kitamura 1, M Tsuboi 1
PMCID: PMC1385098  PMID: 2925225

Abstract

A serum factor, which inhibits haemolysis of the buffer control used in a C3 haemolytic assay, was found in a C3-deficient subject (C3D). Since the buffer control consisted of EAC142, C5 and C6-9 reagent (C6-9R, prepared by treatment of guinea-pig serum with KSCN and hydrazine hydrate), the factor seems to be an inhibitor of C3-independent immune haemolysis. Gel filtration and CM cellulose column chromatography of C3D serum suggested that the inhibitor may be C8. The inhibition was not observed in C8-depleted C3D serum. Furthermore, isolated C8 was found to inhibit haemolysis of EAC142 by C5 and C6-9R in a dose-dependent fashion. Thus, C8 was found to be an inhibitor of C3-independent immune haemolysis in the assay. Further studies revealed that C8 also inhibits haemolysis of EAC142 by C3, C5 and C6-9R (C3 assay system) or that of EAC1423 by C5 and C6-9R (C5 assay system), indicating that C3 or C5 haemolytic activity can be underestimated by the presence of C8 in a sample. C8 did not inhibit haemolysis in the assay system when isolated C6-C9 of human origin were used, but did inhibit haemolysis when isolated C6-C9 of guinea-pig origin was used instead of C6-9R. Thus, it was suggested that the incompatibility of human C8 with guinea-pig C6-C9 might be responsible for this phenomenon. Additional experiments for the mechanism clearly showed that human C8 inhibits the haemolysis of EAC1-7 (EA bearing human C1-C5 and guinea-pig C6 and C7) by guinea-pig C8 and C9 by binding to EAC1-7 prior to guinea-pig C8.

Full text

PDF
264

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boyle M. D., Gee A. P., Okada M., Borsos T. Differences in cell-bound C8 sites on chicken erythrocytes measured by their reactivity with guinea pig and human C9. J Immunol. 1980 Dec;125(6):2818–2822. [PubMed] [Google Scholar]
  2. Cooper N. R., Müller-Eberhard H. J. The reaction mechanism of human C5 in immune hemolysis. J Exp Med. 1970 Oct 1;132(4):775–793. doi: 10.1084/jem.132.4.775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Hadding U., Müller-Eberhard H. J. The ninth component of human complement: isolation, description and mode of action. Immunology. 1969 Jun;16(6):719–735. [PMC free article] [PubMed] [Google Scholar]
  4. Inai S., Kitamura H., Hiramatsu S., Nagaki K. Deficiency of the ninth component of complement in man. J Clin Lab Immunol. 1979 Apr;2(1):85–87. [PubMed] [Google Scholar]
  5. Inoue K., Mori T., Yonemasu K. Studies on the C'3d of guinea pig complement. Biken J. 1967 Sep;10(3):143–153. [PubMed] [Google Scholar]
  6. Kitamura H., Inai S. Molecular analysis of the reaction of C9 with EAC1-8: reaction of C9 with EAC1-8. J Immunol. 1974 Dec;113(6):1992–2003. [PubMed] [Google Scholar]
  7. Kitamura H., Matsumoto M., Inai S. Necessity of the divalent cation in the reaction between EAC1-8hu and C9gp. Int Arch Allergy Appl Immunol. 1976;51(2):265–271. doi: 10.1159/000231599. [DOI] [PubMed] [Google Scholar]
  8. Kitamura H., Matsumoto M., Nagaki K. C3-independent immune haemolysis: haemolysis of EAC14oxy2 cells by C5-C9 without participation of C3. Immunology. 1984 Nov;53(3):575–582. [PMC free article] [PubMed] [Google Scholar]
  9. Kitamura H., Nagaki K., Inai S. Further studies on C9 deficiency. J Clin Lab Immunol. 1981 Jul;6(1):7–11. [PubMed] [Google Scholar]
  10. Kitamura H., Nishimukai H., Sano Y., Nagaki K. Study on C3-like factor in the serum of a C3-deficient subject. Immunology. 1984 Feb;51(2):239–245. [PMC free article] [PubMed] [Google Scholar]
  11. Kitamura H., Tsuboi M., Nagaki K. C3-independent immune haemolysis: mechanism of membrane attack complex formation. Immunology. 1986 Sep;59(1):147–151. [PMC free article] [PubMed] [Google Scholar]
  12. Kitamura H., Tsuboi M., Nagaki K. C56 formation in the reaction mixture of isolated complement components through the classical complement pathway. Int Arch Allergy Appl Immunol. 1985;78(1):101–107. doi: 10.1159/000233870. [DOI] [PubMed] [Google Scholar]
  13. Manni J. A., Müller-Eberhard H. J. The eighth component of human complement (C8): isolation, characterization, and hemolytic efficiency. J Exp Med. 1969 Nov 1;130(5):1145–1160. doi: 10.1084/jem.130.5.1145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Podack E. R., Kolb W. P., Müller-Eberhard H. J. Purification of the sixth and seventh component of human complement without loss of hemolytic activity. J Immunol. 1976 Feb;116(2):263–269. [PubMed] [Google Scholar]
  15. Sano Y., Nishimukai H., Kitamura H., Nagaki K., Inai S., Hamasaki Y., Maruyama I., Igata A. Hereditary deficiency of the third component of complement in two sisters with systemic lupus erythematosus-like symptoms. Arthritis Rheum. 1981 Oct;24(10):1255–1260. doi: 10.1002/art.1780241005. [DOI] [PubMed] [Google Scholar]
  16. Schönermark S., Filsinger S., Berger B., Hänsch G. M. The C8-binding protein of human erythrocytes: interaction with the components of the complement-attack phase. Immunology. 1988 Apr;63(4):585–590. [PMC free article] [PubMed] [Google Scholar]
  17. Stolfi R. L. An analogue of guinea pig C8: in vitro generation and inhibitory activity. J Immunol. 1970 May;104(5):1212–1219. [PubMed] [Google Scholar]
  18. Tack B. D., Prahl J. W. Third component of human complement: purification from plasma and physicochemical characterization. Biochemistry. 1976 Oct 5;15(20):4513–4521. doi: 10.1021/bi00665a028. [DOI] [PubMed] [Google Scholar]
  19. Tack B. F., Morris S. C., Prahl J. W. Fifth component of human complement: purification from plasma and polypeptide chain structure. Biochemistry. 1979 Apr 17;18(8):1490–1497. doi: 10.1021/bi00575a016. [DOI] [PubMed] [Google Scholar]
  20. Von Zabern I., Nolte R., Vogt W. Incompatibility between complement components C3 and C5 of guinea-pig and man, an indication of their interaction in C5 activation by classical and alternative C5 convertases. Scand J Immunol. 1979;9(1):69–74. doi: 10.1111/j.1365-3083.1979.tb02708.x. [DOI] [PubMed] [Google Scholar]
  21. Yamamoto K. I. Lytic activity of C5-9 complexes for erythrocytes from the species other than sheep: C9 rather than C8-dependent variation in lytic activity. J Immunol. 1977 Oct;119(4):1482–1485. [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES